Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 175.8 EUR 4.64% Market Closed
Market Cap: 12.1B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sartorius AG
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Cash Paid for Dividends
-€50.7m
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-11%
Carl Zeiss Meditec AG
XETRA:AFX
Cash Paid for Dividends
€181k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stratec SE
XETRA:SBS
Cash Paid for Dividends
-€6.7m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
1%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Cash Paid for Dividends
-€1m
CAGR 3-Years
52%
CAGR 5-Years
30%
CAGR 10-Years
11%
Siemens Healthineers AG
XETRA:SHL
Cash Paid for Dividends
-€1.1B
CAGR 3-Years
-7%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Cash Paid for Dividends
-€33.2m
CAGR 3-Years
-97%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
No Stocks Found

Sartorius AG
Glance View

Market Cap
12.1B EUR
Industry
Health Care

Sartorius AG is a globally recognized leader in the biopharmaceutical and laboratory equipment sectors, dedicated to enhancing the efficiency of research and production processes. Founded in 1870 and headquartered in Göttingen, Germany, this innovative company provides a comprehensive range of products and services that support the life sciences industry—from advanced laboratory instruments to high-quality access materials for biopharmaceutical manufacturing. As the demand for biotechnological solutions continues to rise, particularly in response to global health challenges, Sartorius stands out by offering critical tools and technologies, positioning itself at the forefront of a thriving market with sustainable growth potential. Investors will find Sartorius particularly attractive due to its robust business model, marked by significant investments in research and development that fuel continuous innovation. The company has experienced impressive revenue growth, bolstered by strategic acquisitions that expand its technological capabilities and market reach. With a committed focus on sustainability and efficiency, Sartorius not only drives profitability but also aligns with the growing investor preference for socially responsible enterprises. As healthcare demands increase and the biopharmaceutical industry evolves, Sartorius AG offers a compelling investment opportunity characterized by a strong market position, strategic foresight, and a commitment to improving human health across the globe.

SRT Intrinsic Value
190.01 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Sartorius AG's Cash Paid for Dividends?
Cash Paid for Dividends
-50.7m EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Cash Paid for Dividends amounts to -50.7m EUR.

What is Sartorius AG's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-11%

Over the last year, the Cash Paid for Dividends growth was 48%. The average annual Cash Paid for Dividends growth rates for Sartorius AG have been -2% over the past three years , -4% over the past five years , and -11% over the past ten years .

Back to Top